| CAT # | Product Name | Description |
| CPD100230 | JBJ-04-125-02 R-isomer | |
| CPD3232 | NTN21277 | NTN21277, also known as Gefitinib-based PROTAC 3 is a VHL-recruiting PROTAC that induces the degradation of EGFR and EGFR mutants with DC50 of 11.7 nM and 22.3 nM for HCC827 cell (Exon 19 del) and H3255 cell (L858R). |
| CPDB3615 | Nazartinib; EGF816; NVS-816 | Nazartinib, also known as EGF816 and NVS-816, is an orally available, irreversible, third-generation, mutant-selective epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. |
| CPDB0934 | EAI-045 | EAI045 ia a potent and selective EGFR inhbitor. EAI045 targets selected drug-resistant EGFR mutants but spares the wild-type receptor. EAI045 inhibits L858R/T790M-mutant EGFR with low-nanomolar potency in biochemical assays. |
| CPDB0101 | Poziotinib | Formulations containing poziotinib are under investigation in clinical trials for the treatment of EGFR-mutant lung adenocarcinoma. |
| CPDB0137 | Osimertinib Mesylate | Osimertinib, also known as mereletinib and AZD-9291, is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors. |
